News and Stories

September 27, 2023

The Basics of Cholesterol: Understanding its Role in Your Health

Almost 2 in 5 adults have high cholesterol, which puts them at risk for serious health conditions like heart disease and stroke¹.

Read More
September 12, 2023

Lab Tests for Healthy Aging

Curious about staying youthful? The secret is a healthy lifestyle. It is never too late to get started!

Read More
September 01, 2023

Celebrating Compassion and Collaboration: HNL Lab Medicine and NCC’s Back-to-School Pantry Drive

In a heartwarming display of unity and generosity, HNL Lab Medicine is thrilled to share the exciting news of its partnership with Northampton Community College (NCC) for a remarkable Back-to-School Pantry Drive.

Read More
August 28, 2023

Martin K. Till Featured on Health Care Power List

Martin K. Till, President and CEO of HNL Lab Medicine, has been named a top leader on Lehigh Valley Business’ Health Care Power List.  

Read More
August 16, 2023

Why Blood Tests Are Important for Children: Top Tests Explained

Blood tests are diagnostic tools that help pediatricians assess your child’s health. 

Read More
News and Stories

October 28, 2022

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas. As a poor survival rate characterizes these aggressive lymphomas, early detection and treatment is vital. Fluorescence in situ hybridization (FISH) is a sensitive method to detect smaller genomic changes associated with various hematological malignancies and solid tumors. The high sensitivity of FISH analysis detects low-level clones and identifies prognostically and therapeutically important genetic abnormalities. This new in-house panel delivers prompt results and complements HNL Genomics offerings.


The non-Hodgkin lymphoma FISH panel detects IGH gene translocations or rearrangements involving the 14q32 locus. Included in this group are follicular lymphoma (FL), Burkitt Lymphoma (BL), and diffuse large B-cell lymphoma (DLBCL). The characteristic chromosome abnormality t(14;18) resulting in IGH/BCL2 fusion is seen in about 80% of FL and about 20-30% of DLBCL. A majority of patients with BL harbor the characteristic t(8;14), resulting in c-MYC/IGH fusion. BCL6 gene rearrangements are also associated with B-cell lymphoma. Cyclin D1 gene rearrangements, especially the t(11;14), distinguish mantle cell lymphoma (ML) from other lymphoproliferative disorders, hence are diagnostic for ML.


There are several advantages of FISH technology over routine chromosome analysis, including the ability of FISH technology to detect genomic abnormalities in non-viable and non-dividing tissues, rapid turnaround time, and increased resolution. However, FISH technology is complementary to routine chromosome analysis and cannot substitute routine chromosome analysis for the diagnosis of cancer.
Providers suspecting non-Hodgkin lymphoma can order this panel easily using the test code FPNHL. Our genetic testing experts are available to assist with any questions. The average turnaround time for our non-Hodgkin lymphoma FISH panel is 3-4 days. Results are available in EPIC.

Test Summary

  • Non-Hodgkin lymphoma FISH panel
  • Detects most common abnormalities related to Non-Hodgkins Lymphoma (NHL) by chromosome analysis and FISH testing.
  • Test Code FPNHL
  • Turnaround time: 3-4 days

Time matters to your patients. HNL Lab Medicine delivers patient results quickly and conveniently. Please take advantage of our newly available non-Hodgkin lymphoma FISH panel to provide superior patient care.

For questions or assistance, please call 877-402-4221. For technical questions related to this test, please ask for Technical Support between the hours of 8 a.m. to 4:30 p.m. For general inquiries, Customer Care is available to assist at any time.

Following are the probes included in the NHL panel.